Stoke Therapeutics Investor Relations Material

Stoke Therapeutics Inc. is a biotechnology firm focused on innovative treatments for severe genetic diseases by enhancing protein expression through RNA-based medicines. The company leverages its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology to develop antisense oligonucleotides (ASOs) aimed at selectively restoring protein levels. This approach is particularly geared towards addressing diseases caused by haploinsufficiencies, where a loss of about 50% of normal protein levels leads to illness. The company is headquartered in Bedford, Massachusetts, and its shares are listed on the Nasdaq.